Enhanced peripheral levels of BDNF and proBDNF: elucidating neurotrophin dynamics in cocaine use disorder.

Journal

Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835

Informations de publication

Date de publication:
04 Jan 2024
Historique:
received: 07 07 2023
accepted: 05 12 2023
revised: 18 11 2023
medline: 5 1 2024
pubmed: 5 1 2024
entrez: 4 1 2024
Statut: aheadofprint

Résumé

Brain-derived neurotrophic factor (BDNF) and its precursor, proBDNF, are known to significantly contribute to brain homeostasis, neuroplasticity, and neuronal remodeling. Although these neurotrophins are thought to have opposing roles, both play a critical part in shaping long-lasting behavioral changes following substance use. In this context, our study sought to explore the implications of these neurotrophins in the pathophysiology of cocaine use disorder (CUD). We conducted a case-control study, which included 28 individuals seeking treatment for CUD and 38 matched healthy participants. We measured peripheral neurotrophin concentrations via an enzyme-linked immunosorbent assay. Additionally, all participants were screened for cocaine-associated pathways (e.g., cocaine intake, craving intensity), along with associated psychopathological data. Our findings highlighted an increased concentration of BDNF and proBDNF in CUD individuals when compared to healthy controls (BDNF: 18092.80 ± 6844.62 vs. 11334.42 ± 5061.85 pg/ml, p < 0.001; proBDNF: 87.03 ± 33.23 vs. 55.70 ± 23.26 ng/ml, p < 0.001). We further corroborated the relationship between neurotrophin levels and CUD using a linear regression model. Nevertheless, there was no significant difference in the proBDNF to BDNF ratio between the two groups. Interestingly, our study also demonstrated the influence of factors like usage of psychotropic medications, history of psychiatric hospitalizations, and psychiatric diagnoses on neurotrophin dynamics. In conclusion, our study underscores the significance of neurotrophin fluctuations in CUD. The observed increase in BDNF and proBDNF levels could play a pivotal role in driving craving and relapse risk. Thus, a nuanced understanding of these neurobiological underpinnings in CUD might contribute to the development of more targeted and effective therapeutic strategies.

Identifiants

DOI: 10.1038/s41380-023-02367-7 PMID: 38177347
pubmed: 38177347
doi: 10.1038/s41380-023-02367-7
pii: 10.1038/s41380-023-02367-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023. The Author(s).

Références

Peacock A, Leung J, Larney S, Colledge S, Hickman M, Rehm J, et al. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction. 2018;113:1905–26.
pubmed: 29749059 doi: 10.1111/add.14234
Koob GF, Le Moal M. Addiction and the brain antireward system. Annu Rev Psychol. 2008;59:29–53.
pubmed: 18154498 doi: 10.1146/annurev.psych.59.103006.093548
Ornell F, Hansen F, Schuch FB, Pezzini Rebelatto F, Tavares AL, Scherer JN, et al. Brain-derived neurotrophic factor in substance use disorders: a systematic review and meta-analysis. Drug Alcohol Depend. 2018;193:91–103.
pubmed: 30347311 doi: 10.1016/j.drugalcdep.2018.08.036
Miuli A, d’Andrea G, Pettorruso M, Mancusi G, Mosca A, Di Carlo F, et al. From a cycle to a period: the potential role of BDNF as plasticity and phase-specific biomarker in cocaine use disorder. Curr Neuropharmacol. 2022;20:2024–8.
pubmed: 35034597 pmcid: 9886838 doi: 10.2174/1570159X20666220114152052
Hempstead BL. Brain-derived neurotrophic factor: three ligands, many actions. Trans Am Clin Climatol Assoc. 2015;126:9–19.
pubmed: 26330656 pmcid: 4530710
Casarotto PC, Girych M, Fred SM, Kovaleva V, Moliner R, Enkavi G, et al. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell. 2021;184:1299–.e19.
pubmed: 33606976 pmcid: 7938888 doi: 10.1016/j.cell.2021.01.034
Fang H, Chartier J, Sodja C, Desbois A, Ribecco-Lutkiewicz M, Walker PR, et al. Transcriptional activation of the human brain-derived neurotrophic factor gene promoter III by dopamine signaling in NT2/N neurons. J Biol Chem. 2003;278:26401–9.
pubmed: 12738784 doi: 10.1074/jbc.M211539200
Anastasia A, Deinhardt K, Chao MV, Will NE, Irmady K, Lee FS, et al. Val66Met polymorphism of BDNF alters prodomain structure to induce neuronal growth cone retraction. Nat Commun. 2013;4:2490.
pubmed: 24048383 doi: 10.1038/ncomms3490
Kowiański P, Lietzau G, Czuba E, Waśkow M, Steliga A, Moryś J. BDNF: a key factor with multipotent impact on brain signaling and synaptic plasticity. Cell Mol Neurobiol. 2018;38:579–93.
pubmed: 28623429 doi: 10.1007/s10571-017-0510-4
Le Blanc J, Fleury S, Boukhatem I, Bélanger JC, Welman M, Lordkipanidzé M. Platelets selectively regulate the release of BDNF, but not that of its precursor protein, proBDNF. Front Immunol. 2020;11:575607.
pubmed: 33324399 pmcid: 7723927 doi: 10.3389/fimmu.2020.575607
Chacón-Fernández P, Säuberli K, Colzani M, Moreau T, Ghevaert C, Barde YA. Brain-derived neurotrophic factor in megakaryocytes. J Biol Chem. 2016;291:9872–81.
pubmed: 27006395 pmcid: 4858990 doi: 10.1074/jbc.M116.720029
Diniz CRAF, Casarotto PC, Resstel L, Joca SRL. et al. Beyond good and evil: a putative continuum-sorting hypothesis for the functional role of proBDNF/BDNF-propeptide/mBDNF in antidepressant treatment.Neurosci Biobehav Rev.2018;90:70–83.
pubmed: 29626490 doi: 10.1016/j.neubiorev.2018.04.001
Fonseca F, Mestre-Pinto JI, Rodríguez-Minguela R, Papaseit E, Pérez-Mañá C, Langohr K, et al. BDNF and cortisol in the diagnosis of cocaine-induced depression. Front Psychiatry. 2022;13:836771.
pubmed: 35370811 pmcid: 8964529 doi: 10.3389/fpsyt.2022.836771
Angelucci F, Ricci V, Pomponi M, Conte G, Mathé AA, Attilio Tonali P, et al. Chronic heroin and cocaine abuse is associated with decreased serum concentrations of the nerve growth factor and brain-derived neurotrophic factor. J Psychopharmacol. 2007;21:820–5.
pubmed: 17715210 doi: 10.1177/0269881107078491
Corominas-Roso M, Roncero C, Eiroa-Orosa FJ, Gonzalvo B, Grau-Lopez L, Ribases M, et al. Brain-derived neurotrophic factor serum levels in cocaine-dependent patients during early abstinence. Eur Neuropsychopharmacol. 2013;23:1078–84.
pubmed: 23021567 doi: 10.1016/j.euroneuro.2012.08.016
D’Sa C, Fox HC, Hong AK, Dileone RJ, Sinha R. Increased serum brain-derived neurotrophic factor is predictive of cocaine relapse outcomes: a prospective study. Biol Psychiatry. 2011;70:706–11.
pubmed: 21741029 pmcid: 3186871 doi: 10.1016/j.biopsych.2011.05.013
von Diemen L, Kapczinski F, Sordi AO, de Magalhães Narvaez JC, Guimarães LSP, Kessler FHP, et al. Increase in brain-derived neurotrophic factor expression in early crack cocaine withdrawal. Int J Neuropsychopharmacol. 2014;17:33–40.
doi: 10.1017/S146114571300103X
Bath KG, Schilit A, Lee FS. Stress effects on BDNF expression: effects of age, sex, and form of stress. Neuroscience. 2013;239:149–56.
pubmed: 23402850 doi: 10.1016/j.neuroscience.2013.01.074
Jamal M, Van der Does W, Elzinga BM, Molendijk ML, Penninx BWJH. Association between smoking, nicotine dependence, and BDNF Val66Met polymorphism with BDNF concentrations in serum. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2015;17:323–9.
doi: 10.1093/ntr/ntu151
Miuli A, Mancusi G, Pettorruso M, Di Carlo F, Clemente K, Di Meo I, et al. Impact of sleep disorders and disease duration on neurotrophins levels in cocaine use disorder. Neurosci Lett. 2022;786:136805.
pubmed: 35850320 doi: 10.1016/j.neulet.2022.136805
Naegelin Y, Dingsdale H, Säuberli K, Schädelin S, Kappos L, Barde YA. Measuring and validating the levels of brain-derived neurotrophic factor in human serum. eNeuro. 2018;5:ENEURO.0419-17.2018.
Yang J, Siao CJ, Nagappan G, Marinic T, Jing D, McGrath K, et al. Neuronal release of proBDNF. Nat Neurosci. 2009;12:113–5.
pubmed: 19136973 pmcid: 2737352 doi: 10.1038/nn.2244
Zhao G, Zhang C, Chen J, Su Y, Zhou R, Wang F, et al. Ratio of mBDNF to proBDNF for differential diagnosis of major depressive disorder and bipolar depression. Mol Neurobiol. 2017;54:5573–82.
pubmed: 27613282 doi: 10.1007/s12035-016-0098-6
Martinotti G, Pettorruso M, Montemitro C, Spagnolo PA, Acuti Martellucci C, Di Carlo F, et al. Repetitive transcranial magnetic stimulation in treatment-seeking subjects with cocaine use disorder: a randomized, double-blind, sham-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2022;116:110513.
pubmed: 35074451 doi: 10.1016/j.pnpbp.2022.110513
Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br J Addict. 1991;86:1119–27.
pubmed: 1932883 doi: 10.1111/j.1360-0443.1991.tb01879.x
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13.
pubmed: 11556941 pmcid: 1495268 doi: 10.1046/j.1525-1497.2001.016009606.x
Park H, Poo M. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci. 2013;14:7–23.
pubmed: 23254191 doi: 10.1038/nrn3379
Russo SJ, Mazei-Robison MS, Ables JL, Nestler EJ. Neurotrophic factors and structural plasticity in addiction. Neuropharmacology. 2009;56:73–82.
pubmed: 18647613 doi: 10.1016/j.neuropharm.2008.06.059
Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2009;5:311–22.
pubmed: 19498435 doi: 10.1038/nrneurol.2009.54
Cunha C, Brambilla R, Thomas KL. A simple role for BDNF in learning and memory? Front Mol Neurosci. 2010;3:1.
pubmed: 20162032 pmcid: 2821174
Cunha-Oliveira T, Rego AC, Oliveira CR. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Res Rev. 2008;58:192–208.
pubmed: 18440072 doi: 10.1016/j.brainresrev.2008.03.002
Graham DL, Edwards S, Bachtell RK, DiLeone RJ, Rios M, Self DW. Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-administration and relapse. Nat Neurosci. 2007;10:1029–37.
pubmed: 17618281 doi: 10.1038/nn1929
Li X, Wolf ME. Multiple faces of BDNF in cocaine addiction. Behav Brain Res. 2015;279:240–54.
pubmed: 25449839 doi: 10.1016/j.bbr.2014.11.018
Grimm JW, Lu L, Hayashi T, Hope BT, Su TP, Shaham Y. Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci. 2003;23:742–7.
pubmed: 12574402 pmcid: 6741929 doi: 10.1523/JNEUROSCI.23-03-00742.2003
Lu, Dempsey J, Liu SY, Bossert JM, Shaham Y. A single infusion of brain-derived neurotrophic factor into the ventral tegmental area induces long-lasting potentiation of cocaine seeking after withdrawal. J Neurosci. 2004;24:1604–11.
pubmed: 14973246 pmcid: 6730465 doi: 10.1523/JNEUROSCI.5124-03.2004
Pianca TG, Rosa RL, Ceresér KMM, de Aguiar BW, de Abrahão RC, Lazzari PM, et al. Differences in biomarkers of crack-cocaine adolescent users before/after abstinence. Drug Alcohol Depend. 2017;177:207–13.
pubmed: 28618284 doi: 10.1016/j.drugalcdep.2017.03.043
Hirsch GE, Jaskulski M, Hamerski HM, Porto FG, da Silva B, Aita CAM, et al. Evaluation of oxidative stress and brain-derived neurotrophic factor levels related to crack-use detoxification. Neurosci Lett. 2018;670:62–8.
pubmed: 29374540 doi: 10.1016/j.neulet.2018.01.044
Fumagalli F, Di Pasquale L, Caffino L, Racagni G, Riva MA. Repeated exposure to cocaine differently modulates BDNF mRNA and protein levels in rat striatum and prefrontal cortex. Eur J Neurosci. 2007;26:2756–63.
pubmed: 18001273 doi: 10.1111/j.1460-9568.2007.05918.x
Smith MA, Makino S, Kvetnansky R, Post RM. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci. 1995;15:1768–77.
pubmed: 7891134 pmcid: 6578156 doi: 10.1523/JNEUROSCI.15-03-01768.1995
Fernandes BS, Molendijk ML, Köhler CA, Soares JC, Leite CMGS, Machado-Vieira R, et al. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. BMC Med. 2015;13:289.
pubmed: 26621529 pmcid: 4666054 doi: 10.1186/s12916-015-0529-7
Cechova K, Angelucci F, Markova H, Nikolai T, Matuskova V, Laczó J, et al. Ratio of serum proBDNF to BDNF and its association with cognitive performance and brain morphometry in mild cognitive impairment. Alzheimer’s Dement. 2020;16:e046340. https://doi.org/10.1002/alz.046340 .
doi: 10.1002/alz.046340
Numakawa T, Odaka H, Adachi N. Actions of brain-derived neurotrophin factor in the neurogenesis and neuronal function, and its involvement in the pathophysiology of brain diseases. Int J Mol Sci. 2018;19:3650.
pubmed: 30463271 pmcid: 6274766 doi: 10.3390/ijms19113650
Park SW, Phuong VT, Lee CH, Lee JG, Seo MK, Cho HY, et al. Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress. Neurosci Res. 2011;71:335–40.
pubmed: 21893111 doi: 10.1016/j.neures.2011.08.010
Young W. Review of lithium effects on brain and blood. Cell Transplant. 2009;18:951–75.
pubmed: 19523343 doi: 10.3727/096368909X471251
Brunoni AR, Baeken C, Machado-Vieira R, Gattaz WF, Vanderhasselt MA. BDNF blood levels after non-invasive brain stimulation interventions in major depressive disorder: a systematic review and meta-analysis. World J Biol Psychiatry. 2015;16:114–22.
pubmed: 25264290 doi: 10.3109/15622975.2014.958101
Jiang B, He D. Repetitive transcranial magnetic stimulation (rTMS) fails to increase serum brain-derived neurotrophic factor (BDNF). Neurophysiol Clin. 2019;49:295–300.
pubmed: 31208790 doi: 10.1016/j.neucli.2019.05.068
Pettorruso M, Spagnolo PA, Leggio L, Janiri L, Di Giannantonio M, Gallimberti L. et al. Repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex may improve symptoms of anhedonia in individuals with cocaine use disorder: a pilot study. Brain Stimul. 2018;5:1195–7.
doi: 10.1016/j.brs.2018.06.001
Pettorruso M, Martinotti G, Santacroce R, Montemitro C, Fanella F, di Giannantonio M. rTMS reduces psychopathological burden and cocaine consumption in treatment-seeking subjects with cocaine use disorder: an open label, feasibility study. Front psychiatry. 2019;10:621.
pubmed: 31543838 pmcid: 6739618 doi: 10.3389/fpsyt.2019.00621
Pettorruso M, di Giannantonio M, De Risio L, Martinotti G, Koob GF. A light in the darkness: repetitive transcranial magnetic stimulation (rTMS) to treat the hedonic dysregulation of addiction. J Addict Med. 2020;14:272–4.
pubmed: 31725426 pmcid: 7214123 doi: 10.1097/ADM.0000000000000575
Kojima M, Matsui K, Mizui T. BDNF pro-peptide: physiological mechanisms and implications for depression. Cell Tissue Res. 2019;377:73–9.
pubmed: 31076872 doi: 10.1007/s00441-019-03034-6
Poletti S, Aggio V, Hoogenboezem TA, Ambrée O, de Wit H, Wijkhuijs AJM, et al. Brain-derived neurotrophic factor (BDNF) and gray matter volume in bipolar disorder. Eur Psychiatry. 2017;40:33–7.
pubmed: 27837670 doi: 10.1016/j.eurpsy.2016.06.008
Chiou YJ, Huang TL. Brain-derived neurotrophic factor (BDNF) and bipolar disorder. Psychiatry Res. 2019;274:395–9.
pubmed: 30852433 doi: 10.1016/j.psychres.2019.02.051
Angelucci F, Brenè S, Mathé AA. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry. 2005;10:345–52.
pubmed: 15655562 doi: 10.1038/sj.mp.4001637
Martinotti G, Sepede G, Brunetti M, Ricci V, Gambi F, Chillemi E, et al. BDNF concentration and impulsiveness level in post-traumatic stress disorder. Psychiatry Res. 2015;229:814–8.
pubmed: 26277035 doi: 10.1016/j.psychres.2015.07.085
Adzic M, Djordjevic J, Djordjevic A, Niciforovic A, Demonacos C, Radojcic M, et al. Acute or chronic stress induce cell compartment-specific phosphorylation of glucocorticoid receptor and alter its transcriptional activity in Wistar rat brain. J Endocrinol. 2009;202:87–97.
pubmed: 19406955 pmcid: 2695659 doi: 10.1677/JOE-08-0509
Begliuomini S, Casarosa E, Pluchino N, Lenzi E, Centofanti M, Freschi L, et al. Influence of endogenous and exogenous sex hormones on plasma brain-derived neurotrophic factor. Hum Reprod. 2007;22:995–1002.
pubmed: 17251358 doi: 10.1093/humrep/del479

Auteurs

Mauro Pettorruso (M)

Department of Neurosciences, Imaging and Clinical Sciences, University "G. D'Annunzio" of Chieti - Pescara, Chieti, Italy.
Department of Mental Health, ASL 2 Abruzzo Lanciano-Vasto-Chieti, Chieti, Italy.

Andrea Miuli (A)

Department of Neurosciences, Imaging and Clinical Sciences, University "G. D'Annunzio" of Chieti - Pescara, Chieti, Italy. andreamiuli@live.it.
Department of Mental Health, ASL 2 Abruzzo Lanciano-Vasto-Chieti, Chieti, Italy. andreamiuli@live.it.
ORCID: 0000-0003-2431-0460

Katia Clemente (K)

Unit of Clinical Pathology, ASL 2 Abruzzo Lanciano-Vasto-Chieti, Chieti, Italy.

Gianluca Mancusi (G)

Department of Neurosciences, Imaging and Clinical Sciences, University "G. D'Annunzio" of Chieti - Pescara, Chieti, Italy.

Giuseppe Migliara (G)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Francesco Di Carlo (F)

Department of Neurosciences, Imaging and Clinical Sciences, University "G. D'Annunzio" of Chieti - Pescara, Chieti, Italy.

Giulia Pernaci (G)

Department of Neurosciences, Imaging and Clinical Sciences, University "G. D'Annunzio" of Chieti - Pescara, Chieti, Italy.

Teresa Di Crosta (T)

Department of Neurosciences, Imaging and Clinical Sciences, University "G. D'Annunzio" of Chieti - Pescara, Chieti, Italy.

Mario Santorelli (M)

School of Medicine and Surgery, Psychiatric Residency Training Program, University of Milano Bicocca, Monza, 20900, Italy.

Giacomo d'Andrea (G)

Department of Neurosciences, Imaging and Clinical Sciences, University "G. D'Annunzio" of Chieti - Pescara, Chieti, Italy.

Luisa De Risio (L)

Department of Mental Health and Addiction, ASL Roma 5, Rome, Italy.

Mariaceleste Ciavarella (M)

Department of Neurosciences, Imaging and Clinical Sciences, University "G. D'Annunzio" of Chieti - Pescara, Chieti, Italy.

Valentina Baccolini (V)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Ilenia Di Meo (I)

Unit of Clinical Pathology, ASL 2 Abruzzo Lanciano-Vasto-Chieti, Chieti, Italy.

Ivana Cataldo (I)

Unit of Clinical Pathology, ASL 2 Abruzzo Lanciano-Vasto-Chieti, Chieti, Italy.

Stefano L Sensi (SL)

Department of Neurosciences, Imaging and Clinical Sciences, University "G. D'Annunzio" of Chieti - Pescara, Chieti, Italy.

Giovanni Martinotti (G)

Department of Neurosciences, Imaging and Clinical Sciences, University "G. D'Annunzio" of Chieti - Pescara, Chieti, Italy.
Department of Mental Health, ASL 2 Abruzzo Lanciano-Vasto-Chieti, Chieti, Italy.
Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, UK.
ORCID: 0000-0002-7292-2341

Classifications MeSH